Structure Therapeutics——2030年前口服GLP-1获批的强力押注(纳斯达克:GPCR)

· seekingalpha.com

Structure Therapeutics (GPCR):口服GLP-1药物aleniglipron展示16.2%的减重效果;三期试验进行中,现金流充裕。在此阅读对该股票的最新分析。

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI